Partnering is a critical part of AmMax’s integrated growth strategy. It was initially built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. Following the partnership with Evopoint Biosciences, AmMax brought in a next generation ADC with the potential to address multiple solid tumors.
We are actively seeking to license in or acquire additional oncology assets. We are also looking to out-license a number of non-core assets. Please contact email@example.com for further information.